Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STI 6643

Next Previous
X
Search
Drug Profile

STI 6643

Alternative Names: STI-6643

Latest Information Update: 09 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sorrento Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 18 Nov 2021 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT04900519)
  • 01 Jun 2021 Sorrento Therapeutics plans a phase I trial for Solid Tumor(Second line therapy or greater; late stage disease) in August 2021 (NCT04900519),
  • 16 Mar 2021 STI 6643 is available for licensing as of 16 Mar 2021. https://sorrentotherapeutics.com/partnership/ (Sorrento Therapeutics pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top